Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

This study is investigating whether patients with neuroendocrine tumors (NETs) who receive or have received a type of targeted radiation therapy called PRRT (peptide receptor radionuclide therapy) have an increased risk of developing a blood condition called myelodysplastic syndrome (MDS) — a disorder where the bone marrow doesn't produce healthy blood cells. Participants will have serial blood tests to monitor for early genetic changes. **You may be eligible if...** - You have a diagnosis of neuroendocrine tumors (NETs) - You are in good enough health (ECOG 0–3) with a life expectancy of more than 6 months - You fall into one of three groups: you completed PRRT within the past 5 years, you are about to start PRRT within 4 months, or you have been diagnosed with MDS or acute myeloid leukemia after prior PRRT - You are willing to provide blood samples and attend follow-up visits **You may NOT be eligible if...** - You are unwilling to provide blood samples or participate in follow-up as required Talk to your doctor to see if this trial is right for you.